Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of allogeneic iPS cell‐based therapy: from bench to bedside

EMBO Molecular Medicine(2022)10.15252/emmm.202115315Source: DataRank Database

Development of allogeneic iPS cell‐based therapy: from bench to bedside is a research paper published in EMBO Molecular Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.63)OA: goldTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Rita C. R. Perlingeiro ORCID,David H. McKenna ORCID

Live enrichment

PubMed:36479608 PMC:PMC9906386 OpenAlex:https://openalex.org/W4311202858

HHS ¦ National Institutes of Health

Grant: R01 AR071439

U.S. Department of Defense

Grant: W81XWH‐17‐1‐0659

Duchene UK

Grant: 1147094

National Institutes of Health

Grant: 5R01AR071439-04

Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors

FWCI

0.63

Citation Percentile

0.6%

Citation Trend

2022

2024

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202115315

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202115315

publisherhttps://link.springer.com/content/pdf/10.15252/emmm.202115315.pdf

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.15252/emmm.202115315

publisherhttps://link.springer.com/article/10.15252/emmm.202115315/fulltext.html

Fields of Study

Pluripotent Stem Cells ResearchCRISPR and Genetic EngineeringCAR-T cell therapy research0301 basic medicine0303 health sciences03 medical and health sciencesHumansInduced Pluripotent Stem CellsHematopoietic Stem Cell TransplantationCell Differentiation

MeSH Terms

Cell DifferentiationHumansHematopoietic Stem Cell TransplantationInduced Pluripotent Stem Cells

Keywords

SAINTLibrary scienceMedicineGerontologyHistoryArt historyComputer scienceMedicine (General)R5-920Induced Pluripotent Stem CellsGeneticsCommentaryHematopoietic Stem Cell TransplantationHumansCell DifferentiationQH426-470

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Industry, innovation and infrastructure

Development of allogeneic iPS cell‐based therapy: from bench to bedside

FAIR Checklist

Authors (2)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)